<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635424</url>
  </required_header>
  <id_info>
    <org_study_id>10790330DOC</org_study_id>
    <nct_id>NCT03635424</nct_id>
  </id_info>
  <brief_title>Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study</brief_title>
  <official_title>Transcatheter Aortic Valve Replacement (TAVR) With Medtronic TAVR System in Patients With Severe Bicuspid Aortic Valve Stenosis and at Low Predicted Risk of Mortality With Surgical Aortic Valve Replacement (SAVR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to evaluate the procedural safety and efficacy of the Medtronic
      TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk
      for SAVR
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi‐center, prospective, single arm

      All subjects will be treated with a Medtronic TAVR system. Subject follow-ups will be
      conducted at pre and post-procedure, discharge, 30 days, 1 year, and annually through 10
      years
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure safety: All‐cause mortality or disabling stroke rate</measure>
    <time_frame>30 days</time_frame>
    <description>All‐cause mortality or disabling stroke rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device and Procedure Efficacy: Device success rate</measure>
    <time_frame>7 days</time_frame>
    <description>Device success rate, defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Absence of moderate or severe total prosthetic valve regurgitation (at 18 hours to 7 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All‐cause mortality rate</measure>
    <time_frame>1 year and annually through 10 years</time_frame>
    <description>Rate of all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All stroke (disabling and non‐disabling) rate</measure>
    <time_frame>1 year and annually through 10 years</time_frame>
    <description>Rate of disabling and non-disabling strokes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker implantation rate</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new permanent pacemaker implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Myocardial infarction at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life‐threatening bleeding rate</measure>
    <time_frame>30 days, one year, and annually though 10 years</time_frame>
    <description>Rate of life-threatening bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve endocarditis rate</measure>
    <time_frame>30 days, one year, and annually though 10 years</time_frame>
    <description>Rate of prosthetic valve endocarditis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve thrombosis rate</measure>
    <time_frame>30 days, one year, and annually though 10 years</time_frame>
    <description>Rate of prosthetic valve thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve‐related dysfunction requiring repeat procedure rate</measure>
    <time_frame>30 days, one year, and annually though 10 years</time_frame>
    <description>Rate of valve-related dysfunction requiring repeat procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat hospitalization for aortic valve disease rate</measure>
    <time_frame>30 days, one year, and annually though 10 years</time_frame>
    <description>Rate of repeat hospitalization for aortic valve disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat hospitalization for ascending aorta disease rate</measure>
    <time_frame>30 days, one year, and annually though 10 years</time_frame>
    <description>Rate of repeat hospitalization for ascending aorta disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic performance (mean aortic valve gradient) by Doppler echocardiography</measure>
    <time_frame>Baseline, 30 days, one year, and annually though 5 years, and at years 7 and 10</time_frame>
    <description>Change in hemodynamic performance metrics by Doppler echocardiography measured by mean aortic valve gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemodynamic performance (effective orifice area) by Doppler echocardiography</measure>
    <time_frame>Baseline, 30 days, one year, and annually though 5 years, and at years 7 and 10</time_frame>
    <description>Change in hemodynamic performance metrics by Doppler echocardiography measured by effective orifice area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemodynamic performance (degree of total, peri, and transvalvular prosthetic regurgitation) by Doppler echocardiography</measure>
    <time_frame>Baseline, 30 days, one year, and annually though 5 years, and at years 7 and 10</time_frame>
    <description>Change in hemodynamic performance metrics by Doppler echocardiography measured by degree of total, peri, and transvalvular prosthetic regurgitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) functional classification</measure>
    <time_frame>Baseline, 30 days, one year, and annually though 5 years, and at years 7 and 10</time_frame>
    <description>Change in NYHA functional classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related quality of life as assessed by Kansas City Cardiomyopathy (KCCQ) instrument</measure>
    <time_frame>Baseline, 30 days, one year, annually through 5 years</time_frame>
    <description>Change in health-related quality of life assessed by Kansas City Cardiomyopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related quality of life as assessed by EQ-5D survey</measure>
    <time_frame>Baseline, 30 days, and one year</time_frame>
    <description>Change in health-related quality of life as assessed by EQ-5D survey</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Bicuspid Aortic Valve</condition>
  <arm_group>
    <arm_group_label>Medtronic TAVR Systems</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic TAVR Systems</intervention_name>
    <description>Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems</description>
    <arm_group_label>Medtronic TAVR Systems</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe aortic stenosis, defined as follows:

               1. For symptomatic patients:

                  Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean
                  gradient ≥40 mmHg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic
                  echocardiography at rest

               2. For asymptomatic patients:

             Very severe aortic stenosis with an aortic valve area of ≤1.0 cm2 (or aortic valve
             area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient
             ≥60 mmHg by transthoracic echocardiography at rest, OR

             Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean
             gradient ≥40 mmHg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic
             echocardiography at rest, AND an exercise tolerance test that demonstrates a limited
             exercise capacity, abnormal BP response, or arrhythmia OR

             Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean
             gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic
             echocardiography at rest, AND a left ventricular ejection fraction &lt;50%.

          2. Patient is considered low risk for SAVR, where low risk is defined as predicted risk
             of mortality for SAVR &lt;3% at 30 days per multidisciplinary local heart team
             assessment.

          3. Bicuspid aortic valve anatomy (all sub‐types) confirmed by MDCT.

          4. The subject and the treating physician agree that the subject will return for all
             required post‐procedure follow‐up visits.

        Exclusion Criteria:

          1. Any condition considered a contraindication for placement of a bioprosthetic valve
             (eg, subject is indicated for mechanical prosthetic valve).

          2. Age less than 60 years

          3. A known hypersensitivity or contraindication to any of the following that cannot be
             adequately pre-medicated:

               1. aspirin or heparin (HIT/HITTS) and bivalirudin

               2. ticlopidine and clopidogrel

               3. Nitinol (titanium or nickel)

               4. contrast media

          4. Blood dyscrasias as defined: leukopenia (WBC &lt;1000 mm3), thrombocytopenia (platelet
             count &lt;50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or
             hypercoagulable states.

          5. Ongoing sepsis, including active endocarditis.

          6. Any percutaneous coronary or peripheral interventional procedure with a bare metal
             stent or drug eluting stent performed within 30 days prior to screening committee
             approval.

          7. Multivessel coronary artery disease with a Syntax score &gt;22 and/or unprotected left
             main coronary artery.

          8. Symptomatic carotid or vertebral artery disease or successful treatment of carotid
             stenosis within 10 weeks of Heart Team assessment.

          9. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
             mechanical hemodynamic support.

         10. Recent (within 2 months of Heart Team assessment) cerebrovascular accident (CVA) or
             transient ischemic attack (TIA).

         11. Gastrointestinal (GI) bleeding that would preclude anticoagulation.

         12. Subject refuses a blood transfusion.

         13. Severe dementia (resulting in either inability to provide informed consent for the
             study/procedure, prevents independent lifestyle outside of a chronic care facility, or
             will fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits).

         14. Estimated life expectancy of less than 24 months due to associated non-cardiac
             co-morbid conditions.

         15. Other medical, social, or psychological conditions that in the opinion of the
             investigator precludes the subject from appropriate consent or adherence to the
             protocol required follow-up exams.

         16. Currently participating in an investigational drug or another device study (excluding
             registries).

         17. Evidence of an acute myocardial infarction ≤30 days before the study procedure due to
             unstable coronary artery disease (WHO criteria).

         18. Need for emergency surgery for any reason.

         19. Subject is pregnant or breast feeding.

         20. Subject is legally incompetent, or otherwise vulnerable

             Anatomical exclusion criteria:

         21. Pre-existing prosthetic heart valve in any position.

         22. Severe mitral regurgitation amenable to surgical replacement or repair.

         23. Severe tricuspid regurgitation amenable to surgical replacement or repair.

         24. Moderate or severe mitral stenosis amenable to surgical replacement or repair.

         25. Hypertrophic obstructive cardiomyopathy with left ventricular outflow gradient.

         26. Prohibitive left ventricular outflow tract calcification.

         27. Sinus of Valsalva diameter unsuitable for placement of the self-expanding
             bioprosthesis

         28. Aortic annulus diameter of &lt;18 or &gt;30 mm.

         29. Significant ascending aortopathy requiring surgical repair

         30. Ascending aorta diameter &gt; 4.5 cm

             For transfemoral or transaxillary (subclavian) access:

         31. Access vessel mean diameter &lt;5.0 mm for Evolut 23R, 26R, or 29R mm TAV, or access
             vessel mean diameter &lt;5.5 mm for Evolut 34R mm or Evolut PRO 23R, 26R, 29 R mm TAV.
             However, for transaxillary (subclavian) access in patients with a patent LIMA, access
             vessel mean diameter &lt;5.5mm for Evolut 23R, 26R, or 29R mm TAV, or access vessel mean
             diameter &lt;6.0 mm for the Evolut 34R or Evolut PRO TAV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Popma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Reardon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Forrest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Basel Ramlawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winchester Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abrazo Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Robles Hospital &amp; Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPark Medical Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Harrisburg Campus</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Jack and Jane Hamilton Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

